INTRODUCTION
tial of the peptide is investigated by the use of a synthetic peptide representing the peptide ligand sequence (e.g., Recently, random peptide libraries displayed on the Keller et al., 1993; Schellekens et al., 1994 ; Stoute et al., surface of filamentous bacteriophages have been exten-1995) , rather than using the recombinant bacteriophage sively used as a tool to map epitopes or to identify antiitself. This is quite surprising since the selected recombigenic mimics (mimotopes) of disease-specific mononant phage can effectively elicit the production of anticlonal antibodies or polyclonal sera (Smith, 1985; Par- bodies specific to the targeted pathogen (de la Cruz et mley and Smith, 1988; Lenstra et al., 1992; Felici et al., al., 1988; Greenwood et al., 1991; Willis et al., 1993; Mas-1993; Minenkova et al., 1993; Folgori et al., 1994; Scheltico et al., 1993; Minenkova et al., 1993; Zhong et al., lekens et al., 1994; Motti et al., 1994; Stoute et al., 1995; Perham et al., 1995; Meola et al., 1995; Loktev et Dybwad et al., 1995; Perham et al., 1995; Demangel et al., 1996; Demangel et al., 1996; Lundin et al., 1996 Lundin et al., ). al., 1996 Lundin et al., 1996) . These libraries are engiTo our knowledge, there is no study reporting that a neered by the insertion of degenerate oligonucleotides, filamentous recombinant phage which presents a protecencoding a specific number of random amino acids, in tive epitope has the ability to protect an experimental frame with a bacteriophage's gene specifying a virion animal model against disease. However, the direct use surface protein (e.g., Smith, 1985; Parmley and Smith, of a peptide presenting recombinant phage as a vaccine 1988; Haaparanta and Huse, 1995; McConnell et al., to examine the peptide's protective potential would be 1996). Following transfection of Escherichia coli, each of simpler and much less expensive than the conventional the infectious phages displays at its surface a fusion method of peptide synthesis and coupling to a carrier protein containing a single exogenous small peptide seprotein for immunization. quence. As a source of novel ligands of very high diverThe aim of this study was to investigate whether an sity, the bacteriophage display system offers great promepitope presenting recombinant bacteriophage could ise for the development of new effective vaccines diprotect animals against infection by a target pathogen. rected against specific epitopes of a pathogen. However, For this purpose, we took advantage of a well-estabonce a disease-specific epitope/mimotope displaying lished model system based on the ability of a synthetic bacteriophage has been identified, the protective potenpeptide, representing the amino acid region 173-187 from the G glycoprotein of the human respiratory syncytial We show that immunization of mice with a recombinant mL 3,3-diaminobenzidine (Sigma) prepared in TBS and containing 0.03% H 2 O 2 . bacteriophage genetically engineered to display the HRSV-specific epitope induced a strong anti-HRSV imLarge-scale production of a recombinant phage mune response and conferred complete protection of animals against RSV infection. These findings thus demThe recombinant phage 29 was chosen and produced onstrate that recombinant bacteriophages can be used in large quantities for immunization assays. For this puras vaccines to examine the potential of epitopes of interpose, a 2-mL overnight culture of the corresponding E. est in preventing the corresponding disease in animal coli K802 recombinant colony was grown at 37Њ in LB models.
medium containing 40 mg/mL tetracycline (LB/tet). Following centrifugation of the culture at 10,000 g for 10 MATERIALS AND METHODS min, 100 mL of the infectious supernatant was used to infect a 100-mL culture of E. coli K91Kan. The bacterioCells and viruses phage was allowed to adsorb for 10 min at room temperThe human Long (subgroup A; ATCC VR-26) strain of ature, after which the mixture was added to a flask con-RSV was propagated on HEp-2 cells (ATCC CCL-23), as taining 20 mL of LB supplemented with 0.2 mg/mL tetracypreviously described (Trudel et al., 1991) . The bacteriocline. Following a 30-min incubation period at 37Њ, the phage vector Fuse 5 (Scott and Smith, 1990 ) was generculture was further supplemented with tetracycline at a ously provided by Dr. G. Smith (University of Missouri, final concentration of 40 mg/mL and incubated for an Columbia, MO).
additional 16 hr. One milliliter of this preculture was used to subculture 1 L of LB/tet. Following a 16-hr incubation Engineering of recombinant fd phages displaying the period at 37Њ, the culture was centrifuged as above and HRSV epitope the infectious phages contained in the supernatant were precipitated at 4Њ for 16 hr by the addition of 0.15 vol of A recombinant fd phage which displays the 173-187 a solution containing 16.7% polyethylene glycol-8000 and amino acid sequence of the HRSV G glycoprotein as a 3.3 M NaCl. After centrifugation, the phage pellet was fusion to its pIII coat protein was genetically engineered resuspended in 3 mL of phosphate-buffered saline (PBS; by the in-frame insertion of two complementary oligonuGibco), reprecipitated, and then resuspended in less cleotides encoding the amino acid sequence of interest than 1 mL of PBS. The amount of phages produced was and containing SfiI cohesive ends into the SfiI sites of estimated by spectrophotometry, where an OD of 1.0 at gene III of the bacteriophage vector Fuse 5 (Fig. 1A) . E.
260 nm was assumed to represent 1.0 mg/mL (de la Cruz coli K802 competent cells were transfected with the DNA et al., 1988) . mixture and then plated onto LB agar plates containing 40 mg/mL tetracycline. Recombinants were identified by Immunization and protection assays dideoxy-mediated sequencing using the oligonucleotide 5-CCCTCATAGTTAGCGTAACG-3, which complements Five-to six-week-old BALB/c mice were immunized a region of the fd bacteriophage genome located approxithree times, at 14-day intervals, by intraperitoneal injecmately 85 bases upstream from the DNA insert.
tions with 1 mg of wild-type fd, with 1 mg of recombinant bacteriophage 29, or with 4.8 1 10 6 PFU of RSV Long Dot blotting of recombinant bacteriophages strain. The first and subsequent booster doses were given in the presence of complete and incomplete Expression of the 173-187 HRSV G peptide by phage Freund's adjuvant, respectively. Two weeks following the recombinants was assessed by dot blotting of bacteriolast injection, blood samples were drawn and the sera phage-containing supernatants using a monoclonal antifrom different animals within a group were pooled for body (MAb), 18A2B2, which specifically binds to the 174-performance of ELISA. The following day, animals were 187 region of the HRSV G glycoprotein (Trudel et al., intranasally challenged with 1.5 1 10 5 PFU of RSV Long. 1991). For this purpose, culture supernatants (200 mL)
Mice were sacrificed 5 days later and their lungs colcontaining fd recombinants were blotted onto a PVDF lected and homogenized at 0Њ in 10 vol of 199 Hanks', membrane using a Bio-Dot apparatus (Bio-Rad). The 25 mM HEPES, pH 7.8, 218 mM sucrose, 30 mM MgCl 2 membrane was incubated for 1 hr at room temperature containing 0.5 mg/mL fungizone and 50 mg/mL gentain TBS-Tween (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, mycin, using a manual homogenizer. After centrifugation 0.05% Tween 20) containing 1.5% bovine serum albumin at 1500 rpm for 15 min, supernatants were collected and (BSA) and then for an additional hour in a fresh solution tested for the presence of virus by titration assays. containing the MAb 18A2B2. After three washes in TBSTween, the membrane was incubated in TBS-Tween-ELISA BSA containing horseradish peroxidase-coupled goat anti-mouse IgG immune serum (ICN Immunobiologicals, Enzyme-linked immunosorbant assays were performed as previously described (Trudel et al., 1991) . Lisle, IL), washed again, and developed with 0.5 mg/ Briefly, proteins (350 ng/well) from purified RS virus or were expressed as log 10 TCID 50 /g of lung (Taylor et al., 1984) . from HEp-2 cells were adsorbed on flat-bottom microtiter plates overnight at 4Њ. After washing and blocking, 100 mL of serial serum dilutions in PBS containing 10% fetal RESULTS AND DISCUSSION bovine serum and 0.2% (v/v) Tween 20 was added to each well and the plates were incubated for 2 hr at 20Њ.
We recently reported that immunization of mice with a synthetic peptide representing the amino acid region After washing, antigen-antibody complexes were reacted for 2 hr at 20Њ with peroxidase-labeled anti-mouse 173-187 of the G glycoprotein of HRSV completely prevents HRSV replication in the lungs of animals (Trudel immunoglobulin. The reaction was developed with Ophenylenediamine (0.4 mg/mL in 0.1 M sodium citrate, et al., 1991; Simard et al., 1997) . This model system was used to investigate whether an epitope presenting repH 5, containing 0.03% H 2 O 2 ). Absorbance at 492 nm was determined using a STL-Labinstrument spectrophotomecombinant bacteriophage could be directly used as a vaccine to examine the protective potential of the epitope ter (Austria). Titers were expressed as the highest dilution giving an optical density at least 1.5-fold over backof interest in preventing disease in animal models. We thus genetically engineered a recombinant bacterioground.
phage displaying the HRSV protective epitope 173-187 as a fusion to its minor coat protein pIII (Fig. 1A) . ExpresTitration assays sion of the 173-187 epitope by the recombinants selected was assessed by testing the reactivity of bacteriophage Titration assays of lung homogenate supernatants were carried out in quadruplicate in microtiter plates (24 containing supernatants to the MAb 18A2B2, which specifically binds to the 174-187 region of the HRSV G glycowells) containing confluent HEp-2 monolayer cells. Culture medium was removed and replaced by 200 mL of protein (Trudel et al., 1991) . As shown in Fig. 1B , the MAb specifically reacted, and to a similar extent, with 10-fold serial dilutions of viral supernatants. After a 2-hr adsorption period at 37Њ in 5% CO 2 atmosphere, 1.5 mL supernatants containing the recombinant phages 29-32 and with protein extracts from HRSV-infected HEp-2 of medium containing 199 Hanks':Earle MEM (1:1), 1% fetal bovine serum, and 50 mg/mL gentamycin was added cells. In contrast, no reactivity was observed with supernatants containing either wild-type fd phage or protein and the plates were incubated for 5 days. Viral titers 
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The immunogenic and protective potential of the re-
